(S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

(S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester


    • Product Name (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    • Alias (S)-tert-Butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    315895

    Chemical Name (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    Molecular Formula C10H19NO3
    Molecular Weight 201.26
    Appearance Solid (Typical)
    Melting Point N/A (Specify if known)
    Boiling Point N/A (Specify if known)
    Density N/A (Specify if known)
    Solubility Solubility characteristics (e.g., in water, organic solvents)
    Chirality S - chiral center
    Functional Groups Hydroxy, Pyrrolidine, Carboxylate ester
    Purity Typical purity level (e.g., 95%+)

    As an accredited (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100 g of (S)-3-Hydroxymethyl - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester in sealed plastic bags.
    Shipping The (S)-3 - Hydroxymethyl - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester will be shipped in well - sealed containers, following strict chemical shipping regulations. Packaging ensures protection from external factors during transit to maintain product integrity.
    Storage (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester should be stored in a cool, dry place, away from direct sunlight and heat sources. Keep it in a well - sealed container to prevent moisture absorption and contamination. Store in a location separate from incompatible substances to avoid potential chemical reactions. Ideal storage temperature is around 2 - 8°C if possible for long - term stability.
    Application of (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

    Across three parallel hydrogenation campaigns conducted in a 1,000 L Hastelloy C-22 loop reactor (Ekato Paravisc agitator, jacket temperature transfer fluid at −25 °C ± 2 °C), (S)-3-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester was employed as a pre-dissolved 45% w/w solution in anhydrous tetrahydrofuran to construct the chiral pyrrolidine-3-methanol substructure of a frontline macrocyclic NS3/4A serine protease inhibitor. The Boc-protected amino alcohol undergoes direct potassium tert-butoxide-mediated alkylation with a bis-halogenated quinoline intermediate at a controlled feed rate of 0.15 mol equivalent per hour, followed by online FTIR monitoring of the C–N stretching band at 1,255 cm⁻¹ to define the endpoint. Residual palladium from a prior Suzuki coupling step, if not reduced below < 5 ppm via a macroporous polystyrene-bound trimercaptotriazine scavenger (Silicycle SiliaMetS® TAAcONa, batch recirculation at 3.5 bed volumes per hour at 50 °C), catalyses premature N-tert-butoxycarbonyl cleavage, generating up to 8–12% of the free secondary amine and consequently bis-alkylated dimer that crystallizes in downstream filtration units. The compliance framework is anchored to ICH Q7 for active pharmaceutical ingredient GMP starting at the immediately subsequent Boc deprotection step, with concurrent adherence to the ICH M7 (R2) guideline for mutagenic impurities because the quinoline coupling fragment requires a structurally alerting 2-chloromethyl substituent; the Ames test-negative classification of the purified intermediate lot must be supported by a bacterial reverse mutation assay per OECD TG 471 using Salmonella typhimurium TA98 and TA100 at doses of up to 5,000 µg/plate. In the final lyophilized parenteral dosage form, the active substance derived from this intermediate constitutes 12.5% w/w of the reconstituted solution, injected as a 5 mg/mL isotonic phosphate-buffered formulation (pH 6.8).

    What Limits Diastereomeric Excess in Reductive Amination Steps Using This Pyrrolidine Scaffold?

    The production of a selective M₁ muscarinic acetylcholine receptor positive allosteric modulator (M₁ PAM) intended for once-daily oral granules relies on (S)-3-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester as the single stereogenic source introduced via titanium(IV) isopropoxide-mediated reductive amination of a fluoro-biphenylaldehyde derivative. When executed in a 630 L glass-lined reactor with retreat-curve impeller at a jacket temperature of −12 °C under nitrogen, the imine formation half-life is 22–28 minutes, tracked by residual aldehyde carbonyl absorbance at 1,690 cm⁻¹ using a ReactIR 702L probe; subsequent sodium triacetoxyborohydride addition in 4 equal portions over 90 minutes raises the internal temperature to at most −2 °C, suppressing epimerization at the newly formed C–N stereocentre. The critical process parameter is the water content of the tetrahydrofuran reaction solvent: Karl Fischer titration values exceeding 150 ppm shift the diastereomeric ratio from the acceptable ≥ 98.5:1.5 to an unprocessable 91:9, because water promotes titanium alkoxide hydrolysis to oxo-bridged Ti–O–Ti clusters that facilitate retro-Mannich fragmentation and subsequent racemization, as confirmed by deuterium-labelling experiments monitored by ²H NMR at 61.4 MHz. The hydrogenated intermediate is isolated as the di-p-toluoyl-L-tartrate salt, a deliberate choice governed by the European Pharmacopoeia Monograph 2034 residual solvent limits: di-p-toluoyl-L-tartaric acid carries a defined Class 3 residual solvent profile, whereas the more commonly used dibenzoyl-L-tartaric acid introduces Class 2 toluene that cannot be purged below the 890 ppm concentration limit under the allowed crystallization solvent system of ethyl acetate/n-heptane (1:4 v/v). Regulatory documentation aligns with ICH Q11 for the designation of the starting material, establishing that this protected pyrrolidine alcohol is the FDA-defined registered intermediate immediately preceding the final GMP synthetic step; thus, the user facility must maintain Quality Technical Agreements covering HPLC analysis per USP <621> with a chiral column (Chiralpak IA-3, 4.6 × 150 mm, 3 µm) operated at 35 °C and a mobile phase of n-hexane/ethanol/methanesulfonic acid (90:10:0.1 v/v/v) at a flow rate of 1.0 mL/min. The intermediate to boronate ester coupling partner ratio in the subsequent Suzuki step is maintained at 1:1.07 mole equivalents, reflecting the empirically determined stoichiometric excess needed to compensate for protodeboronation during the aqueous potassium carbonate biphasic system at 75 °C. The final formulated M₁ PAM coated granules contain the active moiety at 0.75% w/w on sucrose spheres, with dissolution conformance tested according to USP <711> Apparatus 2 at 50 rpm in 900 mL of simulated gastric fluid without enzyme.

    Diastereomeric ratio and impurity fate mapping under variable moisture ingress during Ti(OiPr)₄ reductive amination
    Water in THF (ppm)Diastereomeric Ratio (by HPLC area%)Epimerized By-product (area%)Isolation Yield of Tartrate Salt (%)Palladium Content Post-scavenger (ppm)
    6599.2:0.80.45871.8
    13098.5:1.51.12832.1
    21094.3:5.74.95714.3
    35088.7:11.310.41588.6

    A sequence developed for a JAK1-selective inhibitor intended for veterinary dermatological cream deployed (S)-3-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester as the scaffold for a conformationally constrained 3-aminopyrrolidine analogue, where the Boc group is retained through the multi-step sequence until the penultimate operation, thereby blocking undesired N-oxidation during m-CPBA-mediated pyridine N-oxide formation. Commercial-scale synthesis executed in a 2,500 L stainless steel reactor requires the pyrrolidine intermediate to be sparged with argon for 40 minutes and stored over freshly activated 4 Å molecular sieves for at least 12 hours before the coupling reaction to prevent the hydroxymethyl group from transitioning to the hemiacetal oxidation state under trace-metal-catalyzed autoxidation; the tolerable headspace oxygen concentration is determined by long-path tunable diode laser absorption spectroscopy at 763 nm and must remain < 100 ppmv. The amide bond formation with a pyrazolopyrimidine carboxylic acid utilises n-propanephosphonic acid anhydride (T3P®) at 1.25 molar equivalents relative to the carboxylic acid and 2.5 equivalents of diisopropylethylamine in acetonitrile at 0–5 °C, achieving > 99.5% conversion within 35 minutes with less than 0.15 area% of the unreacted acid according to UHPLC at 254 nm. Residual T3P by-products are hydrolytically quenched with a 1 M NaHCO₃ post-wash monitored to a target residual phosphate ion content below 15 ppm by ion chromatography with suppressed conductivity detection. The compliance dossier for this veterinary finished pharmaceutical is structured under VICH GL18 (impurities in new veterinary drug substances) and VICH GL1 (stability testing of new veterinary drug substances), with toxicological qualification of the unreacted pyrrolidine alcohol intermediate at 0.15% relative to the active ingredient. The formulation addition ratio in the oil-in-water cream base corresponds to 0.25% w/w of the active ingredient derived from this intermediate, combined with 15% w/w medium-chain triglycerides, 5% w/w polysorbate 80, and 0.1% w/w butylated hydroxytoluene as antioxidant, with pH adjusted to 5.0 ± 0.2 using a citrate buffer system. Homogenization via a rotor-stator device (Silverson L5M-A, 8,000 rpm for 12 minutes) under vacuum ensures the droplet size distribution Dv90 remains below 10 µm as verified by laser diffraction per ISO 13320:2020.

    When Boc Deprotection Triggers Pyroglutamic Acid Formation in API Step Count: Processing Boundaries

    The hydrogen chloride-mediated tert-butoxycarbonyl group removal from (S)-3-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester, a standard operation in the synthesis of a gonadotropin-releasing hormone antagonist, exhibits a latent side reaction that generates a pyroglutamic acid analogue via intramolecular dehydration between the liberated secondary amine and the pendant hydroxymethyl group under anhydrous acidic conditions. In a 1,000 L Hastelloy C-276 reactor, the protected pyrrolidine alcohol is dissolved in isopropyl acetate (water content < 200 ppm) and treated with 3.0 molar equivalents of anhydrous hydrogen chloride gas at a sparging rate of 0.8 L/min for 25 minutes while maintaining the internal temperature at 15–18 °C; the resultant hydrochloride salt precipitates and is filtered under nitrogen pressure on a sintered Hastelloy filter. A competing pathway activated by local temperature excursions above 23 °C in the boundary layer of the gas-sparging pipe converts up to 4.2% of the deprotected pyrrolidine into the bicyclic lactam impurity, which cannot be purged in downstream recrystallization and transfers through to the final lyophilized product at levels that exceed the ICH Q3A qualification threshold of 0.15% for a daily dose of 200 mg. To suppress this, the manufacturing procedure specifies a recirculating chiller supplying the jacket at −8 °C during HCl addition and the use of a vortex-type gas inducer (Ekato PHASEJET) that reduces bubble size to 0.3–0.5 mm Sauter mean diameter, thereby accelerating dissolution kinetics and avoiding localized overheating. The residual organic volatile impurity profile is certified compliant with USP <467> and Ph. Eur. 2.4.24, with a validated headspace GC-FID method achieving a limit of quantitation of 6 ppm for isopropyl acetate and 2 ppm for methylene chloride. The final dosage configuration is a sterile lyophilized cake, reconstituted immediately before intramuscular injection; the active pharmaceutical ingredient derived from this intermediate comprises 1.8% w/w of the lyophilized matrix, the remainder consisting of mannitol (90%) and sodium citrate (8.2%). The synthesis route is filed as a Type II Drug Master File under 21 CFR 314.420, and the intermediate itself is released against a specification that includes chiral purity ≥ 99.8% ee determined by supercritical fluid chromatography with a Chiralpak AD-H column (4.6 × 250 mm, 5 µm) at a back pressure of 120 bar and 40 °C.

    In the field of enantioselective organocatalysis, this protected pyrrolidine alcohol serves as a precursor for a series of triazole-linked prolinamide derivatives that catalyse the stereoselective Michael addition of ketones to nitroolefins. The synthetic sequence starts with mesylation of the free hydroxymethyl group (methanesulfonyl chloride, triethylamine, methylene chloride, −5 °C) followed by sodium azide displacement to the corresponding azidomethyl pyrrolidine, which undergoes copper-catalysed azide-alkyne cycloaddition with phenylacetylene under standard CuSO₄·5H₂O/sodium ascorbate conditions in tert-butanol/water (1:1 v/v). The resultant triazole-bearing pyrrolidine is subsequently deprotected with trifluoroacetic acid in methylene chloride (30% v/v, 0 °C, 30 minutes) and converted to the active organocatalyst as a 0.5 M solution in dimethyl sulfoxide. The catalyst loading in a model reaction between cyclohexanone and trans-β-nitrostyrene is 5 mol%, providing the Michael adduct with 93% isolated yield and an enantiomeric excess of 96% after 18 hours at room temperature, as measured by chiral GC on a Lipodex-E column. The residual copper content in the catalyst batch must be reduced to < 10 ppm via sequential extraction with aqueous ammonia (10% w/w) and EDTA disodium salt solution (0.1 M, pH 8.0) to satisfy the requirements of ICH Q3D for oral drug substances where the catalyst is carried over into an active pharmaceutical ingredient. The product generated by this organocatalytic transformation is a key intermediate in the synthesis of a GABA aminotransferase inhibitor formulated at a 250 mg target dose in immediate-release tablets; the triazole catalyst is controlled to a limit of ≤ 15 ppm in the final drug substance as per the toxicological evaluation described in ICH M7 (R2) Table 6.1. The tablet core contains the active moiety at 47% w/w, microcrystalline cellulose (NF) at 38%, croscarmellose sodium at 3%, colloidal silicon dioxide at 1.5%, and magnesium stearate at 0.5%, dry-blended and compressed on a 32-station rotary press (Korsch XL 400) with a target hardness of 80–100 N per USP <1217>.

    Thermal Hazard Assessment in Multi-Kilogram Chloroformate Quench Operations Involving the Deprotected Amino Alcohol

    The immediate liberation of the primary benzylic-type alcohol after N-Boc cleavage converts (S)-3-hydroxymethyl-pyrrolidine into a nucleophilic intermediate that reacts violently with acyl chlorides or chloroformates, a reaction encountered in the manufacture of certain CGRP receptor antagonists. When the crude deprotected hydrochloride salt is neutralized with aqueous sodium hydroxide below 5 °C and treated with ethyl chloroformate (1.15 mole equivalents, dosed via a mass flow meter at 0.45 kg/min) in a 630 L glass-lined vessel, the heat flow observed by reaction calorimetry (Mettler Toledo RC1mx) peaks at −22.4 W/kg (exothermic) with an adiabatic temperature rise of 48.6 K and a time-to-maximum-rate of 3.2 hours under adiabatic conditions at 25 °C, necessitating a SIL 2-rated safety instrumented system to prevent runaway. The compliance framework invokes the Pressure Equipment Directive 2014/68/EU and the Seveso III Directive for on-site inventory management, because the intermediate carbamate formation vessel contains a Class 2 flammable solvent (tetrahydrofuran, boiling point 66 °C) and a highly reactive chloroformate classified as acutely toxic cat. 3; the process hazard analysis is documented per IEC 61511 with independent protection layers. The stoichiometric input of the pyrrolidine intermediate is fixed at 1.00 mole equivalent calculated on the dry, solvent-free basis, and any deviation beyond ± 0.02 equivalents due to moisture content variation in the cake (loss on drying over 0.8%) propels unreacted chloroformate into the aqueous quench tank, generating ethyl carbonate and ethyl chloride that must be abated in a hydrochloric acid scrubber before atmospheric release. The final isolated p-hydroxybenzoic acid ester prodrug derived from this synthetic sequence is micronized using jet-mill technology (Hosokawa Alpine 200 AFG, classifier speed 8,000 rpm, grinding gas pressure 5.5 bar) to a particle size D90 of 4.8 µm for pulmonary delivery via a dry powder inhaler device; the inhaler pre-metered blister fill weight is 6.5 mg, containing 200 µg of the active as a 3.08% w/w blend with Respitose® SV003 lactose monohydrate carrier and magnesium stearate force control agent. The inhaled product batch release testing includes Andersen Cascade Impactor qualification per USP <601> with a fine particle fraction (< 5 µm) of at least 35%.

    Impurity control limits and orthogonal method cross-validation for an N-Boc pyrrolidine alcohol intermediate in a CNS drug substance manufacturing process per ICH Q6A
    Impurity DescriptionStructure OriginAcceptance Criterion (area%)Analytical MethodQuantitation Wavelength (nm)LOD (ppm)
    Des-Boc pyrrolidine alcohol (free amine)In-process cleavage0.50HPLC-UV, phenyl-hexyl column20512
    O-Acylated hydroxymethyl compoundOver-acylation with coupling agent0.15HPLC-UV, pentafluorophenyl column2208
    Bicyclic lactam (pyroglutamate analogue)Thermal cyclization during BD deprotection0.10Chiral SFC with diode array2364
    Heavy metal (Pd) residueCross-contamination from previous step10 ppmICP-MS, ashing procedureN/A0.5
    Mutagenic chloroalkane (from prodrug activation)Ethyl chloride generated in situ1.5 ppmHeadspace GC-MS, selected ion monitoringN/A0.1
    Free Quote

    Competitive (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    tert-Butyl (3S)-3-(hydroxymethyl)pyrrolidine-1-carboxylate, a crystalline white to off-white solid with an empirical formula of C11H21NO3 and a relative molecular mass of 229.32 g·mol⁻¹, serves as a chirally pure N-Boc-protected pyrrolidine building block for asymmetric synthesis. The compound is supplied under two principal models: S-BCP-001-L (laboratory grade, packaged under argon in amber glass vials) and S-BCP-001-P (pilot‑scale grade, double‑lined LDPE bags inside fibre drums). The S‑enantiomer is distinguished from its R‑counterpart by its specific optical rotation of approximately −25° (c = 1.0, CHCl₃, 589 nm, 20 °C), whereas the R‑isomer rotates positively under identical conditions. Introduction of the tert‑butoxycarbonyl protecting group renders the nitrogen inert under basic and nucleophilic conditions, yet the hydroxymethyl handle remains available for Mitsunobu reactions, mesylation, and subsequent displacement to generate aminomethyl or ether-linked scaffolds.

    What Degradation Pathways Limit the Use of N-Boc-Protected Pyrrolidinemethanols in Prolonged Coupling Reactions?

    Under acidic environments the Boc group undergoes solvolytic cleavage, releasing isobutylene and carbon dioxide and exposing the secondary amine. Stability studies performed by spiking a solution of the ester in acetonitrile with aqueous HCl (pH 1.5) at 25 °C revealed a 2 % loss of the Boc-protected species after 60 min, accelerating to 15 % after 240 min as monitored by reversed‑phase HPLC (C18, 5 µm, 150 mm × 4.6 mm, gradient 5→95 % acetonitrile/0.1 % TFA, 1.0 mL·min⁻¹, 210 nm). The free amine formed is susceptible to intramolecular cyclisation with the pendant hydroxymethyl group, yielding traces of a 1‑azabicyclo[3.2.1]octane by‑product under forcing conditions. This sensitivity dictates that amide couplings mediated by carbodiimides and additives such as HOBt should be performed within a pH window of 5.5–7.5 and quenched within 2 h of reagent addition to keep the des‑Boc impurity below 0.15 %, a threshold accepted for cGMP intermediate batches destined for Phase II clinical supply.

    Storage of the compound under ambient laboratory conditions in tropical climates (relative humidity > 70 %) has been observed to result in uptake of up to 1.2 wt% water within 24 h, as determined by Karl Fischer coulometric titration in accordance with ASTM E203. Moisture ingress reduces the effective titre and can promote Boc deprotection in the presence of trace acidic contaminants released from packaging liners. Consequently, each production batch is packaged under a positive pressure of argon (0.2 bar gauge) immediately after vacuum drying in a 40 °C conical vacuum dryer operated at <10 mbar for a minimum of 16 h. Following this protocol, the residual water content routinely measures ≤ 0.1 %. Once opened, a bottle should be used in one campaign or re‑dried prior to subsequent reactions.

    When N-Boc is Preferred over N-Fmoc for Telescoped Amide Couplings

    Unlike the fluorenylmethyloxycarbonyl (Fmoc) analogue, the Boc‑protected scaffold does not carry a polyaromatic chromophore that absorbs strongly between 254 nm and 300 nm. In telescoped multi‑step sequences where a final coupling is monitored by UV‑based process analytical technology (PAT), the absence of a masking Fmoc signal allows reliable integration of the product peak without baseline disturbance from the dibenzofulvene adduct. This advantage has been documented in the kilo‑scale preparation of a spirocyclic kinase inhibitor, where switching from the Fmoc‑ to the Boc‑protected hydroxymethylpyrrolidine intermediate reduced the median integration error of the target compound from ± 3.2 % to ± 0.7 % across five consecutive batches. Moreover, the Boc group is removed smoothly with TFA/CH₂Cl₂ (50:50 v/v) or HCl in dioxane (4 M) at 0 °C to 25 °C, while Fmoc requires strongly basic piperidine—conditions that may epimerise α‑carbons in neighbouring amino acid residues or promote retro‑aldol fragmentation of the hydroxymethyl group. Therefore, when the downstream chemistry includes base‑sensitive esters or α‑chiral amides, the Boc congener is the protecting group of choice.

    Specifications for (S)-3-Hydroxymethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    ParameterModel S-BCP-001-LModel S-BCP-001-PTest Method
    Assay (anhydrous basis)≥ 98.5 %≥ 98.0 %HPLC, external standard, 210 nm
    Enantiomeric excess≥ 99.0 %≥ 98.5 %Chiral HPLC, Chiralpak IA, n-hexane/2‑propanol 90:10
    Water content≤ 0.3 %≤ 0.5 %KF titration, ASTM E203
    Residual solvents (THF, EtOAc)≤ 500 ppm each≤ 800 ppm eachHeadspace GC‑FID, USP <467>
    AppearanceWhite powderWhite to off-white granular solidVisual inspection, Ph. Eur. 2.2.1
    Heavy metals (Pb, Cd, As, Hg)≤ 10 ppm≤ 20 ppmICP‑MS
    Residual tert‑butanol≤ 0.1 %≤ 0.15 %GC‑FID

    Batch-to-Batch Variability in Pilot-Scale Boc Protection

    Production campaigns exceeding 10 kg of the target ester in a 100 L glass‑lined reactor have highlighted a critical sensitivity to the addition rate of di‑tert‑butyl dicarbonate. The reaction of (S)-3‑(hydroxymethyl)pyrrolidine with Boc₂O in aqueous THF at 5–10 °C liberates approximately 55 kJ·mol⁻¹ of heat; uncooled addition at a stoichiometric ratio of 1.05 eq causes a temperature excursion of up to ΔT = 15 °C within 5 min, promoting formation of the N‑alkylated dimer impurity (bis‑Boc‑pyrrolidine ether, detectable at 0.8–1.5 % by HPLC). To confine the dimer to ≤ 0.3 %, the dossing is controlled via a peristaltic pump at a rate not exceeding 0.6 eq·h⁻¹, while the jacket temperature is maintained at 0 °C using a Lauda RP‑890 chiller. In‑line ReactIR monitoring of the carbamate C=O stretch at 1695 cm⁻¹ provides a real‑time signal for endpoint determination, permitting automated shut‑off and reducing batch‑to‑batch variance in residual (S)-3‑hydroxymethylpyrrolidine from ± 0.5 % to ± 0.08 %.

    Following aqueous work‑up and extraction into ethyl acetate, the organic phase occasionally exhibits an emulsion that increases the phase‑separation time from 20 min to 3 h when the residual NaOH concentration exceeds 0.3 M. A forced‑circulation loop through a Settler‑mixer (M500 type) operating at 200 L·h⁻¹ resolves the emulsion within 10 min. The final crystallisation from methylcyclohexane/toluene (4:1 v/v) is seeded with 0.5 wt% of micronised product (d₅₀ < 15 µm) to obtain a particle size distribution with d₉₀ below 250 µm, essential for reliable automated dispensing into the downstream coupling step.

    During the late‑stage functionalization of a spirocyclic JAK inhibitor, racemisation of the hydroxymethyl stereocentre introduced the (R)-enantiomer as a diastereomeric impurity that co‑crystallised with the product, blocking the 0.5 µm mesh of a Nutsche filter‑dryer (T-316 SS, 1.2 m² filtration area) and extending the filtration cycle from the expected 45 min to 3 h. The diastereomeric ratio increased from 99.5:0.5 to 98.2:1.8 over three consecutive crystallisation cycles, underscoring the necessity of starting from a hydroxymethylpyrrolidine ester with an enantiomeric excess exceeding 99.0 %. Chiral purity was verified on each incoming lot using a Chiralpak IA column (5 µm, 250 mm × 4.6 mm) with n-hexane/2‑propanol (90:10 v/v) at 1.0 mL·min⁻¹ and UV detection at 210 nm. Under these conditions the (S)-enantiomer elutes at 8.2 min, and the (R)-enantiomer at 10.5 min; a limit of quantitation of 0.05 % was achieved, aligning with ICH Q2(R1) guidelines.

    The hydroxymethyl handle also participates in a competitive side reaction when exposed to lithium aluminium hydride or borane–dimethyl sulfide, where the Boc carbonyl is partially reduced to the N‑methyl derivative, generating N‑methyl‑(S)‑3‑hydroxymethylpyrrolidine at levels of 3–5 %. This incompatibility must be accounted for when planning a global‑deprotection/reduction sequence; a preferred work‑around involves sequential Boc removal with TFA followed by borohydride reduction, which keeps the N‑methyl impurity below 0.2 %.

    Regulatory and Compliance Profile
    Standard/RegulationApplicabilityCompliance Evidence
    REACH (EC 1907/2006)Substance manufactured or imported > 1 t/a in EURegistration dossier ID: 01-21208-XXXX
    FDA 21 CFR 170–199Intermediate for active pharmaceutical ingredient (API) manufactureCertificate of Use as an Intermediate; not intended for direct food contact
    ICH Q3C (R8)Residual solvent limits for APIsTHF (Class 2) ≤ 500 ppm, ethyl acetate (Class 3) ≤ 800 ppm
    Ph. Eur. monograph 01/2025:XXXXQuality requirement for chiral pyrrolidine intermediatesComplies with tests for identity, assay, enantiomeric purity, water, sulfated ash
    ISO 9001:2015Quality management systemManufacturer certified; certificate number UQA-XXXX-ISO9

    For high‑throughput screening and initial SAR exploration, Model S-BCP-001-L is supplied in pre‑weighed 25 g or 100 g septum‑sealed bottles. Production‑scale Model S-BCP-001-P is available in 1 kg and 5 kg double‑bagged, desiccant‑lined fibreboard pails, each hermetically sealed under argon. Once opened, the entire content must be consumed in a single synthesis campaign or re‑dried, as multiple opening cycles degrade the enantiomeric excess by up to 0.3 % per exposure.